Ben-Ammar, Imen et al. “Precision medicine for KRAS wild-type pancreatic adenocarcinomas.” European journal of cancer (Oxford, England : 1990), vol. 197 113497. 15 Dec. 2023, doi:10.1016/j.ejca.2023.113497
Clarke CN, Hall WA, Erickson B, Ahmed G, Thapa B, McFall T, George B, Kurzrock R, Kamgar M. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Ther Adv Med Oncol. 2024 May 19;16:17588359241253113. doi: 10...
首页 / 癌基因 / KRAS / WILD TYPEKRAS(KRAS proto-oncogene, GTPase) KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog)基因是GDP/GTP结合蛋白,比较重要的同家族基因还包括HRAS和NRAS。KRAS与GTP结合呈激活状态,与GDP结合呈关闭状态,KRAS可被生长因子或酪氨酸激酶(如EGFR)短暂活化,活化后的KRAS可以激活下游如...
1.综述:KRAS野生型胰腺导管腺癌之分子病理和靶向治疗机会 KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities Journal:Journal of Experimental & Clinical Cancer Research IF:7.068 PMID:33115526 概要: 胰腺导管腺癌(PDAC)是人类癌症中最致命的类型之一,预后极差,超过90%...
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities Journal:Journal of Experimental & Clinical Cancer Research IF:7.068 PMID:33115526 概要: 胰腺导管腺癌(PDAC)是人类癌症中最致命的类型之一,预后极差...
结直肠癌是发达国家中最常见的恶性肿瘤之一,而KRAS野生型(KRAS wild-type)的转移性结直肠癌约占50%至60%。KRAS基因突变是结直肠癌的常见遗传变异之一,与抗EGFR治疗的耐药性相关。 以前的研究表明,KRAS野生型转移性结直肠癌患者对抗EGFR的单药治疗的响应更好,与KRAS突变型相比。因此,KRAS野生型转移性结直肠癌的一...
图三 全体患者（左）和PFS≤3个月的患者中KEAP1、SMARCA4 和 CDKN2A共突变的比例，图示Wild-type指野生型，Mut指突变型，only指单一共突变STK11也是早期进展患者中常见的共突变，不过详细分析发现，只有当KEAP1和STK11同时突变才与PFS和OS缩短显著相关。TP53也是常见共突变，不过其与疗效无关。图四 KEAP1野生型...
题图来源:站酷海洛PLUS Philip PA, Azar I, Xiu J, et al. Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 2022 Mar 18;clincanres.3581.2021. doi: 10.1158/1078-0432.CCR-21-3581....
6. Topham JT, Tsang ES, Karasinska JM, et al. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Nat Commun. 2022;13(1):5941. (来源:肿瘤瞭望-消化时讯) ...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases. The genetic landscape of KRAS wild type PDAC can be divided into three categories. The first is represented by tumors...